Foundry Partners LLC Cuts Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Foundry Partners LLC decreased its position in Accuray Incorporated (NASDAQ:ARAY - Free Report) by 17.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,795,645 shares of the medical equipment provider's stock after selling 387,770 shares during the period. Foundry Partners LLC owned 1.75% of Accuray worth $3,214,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of ARAY. Acuitas Investments LLC raised its position in Accuray by 100.4% in the 1st quarter. Acuitas Investments LLC now owns 1,420,207 shares of the medical equipment provider's stock worth $2,542,000 after purchasing an additional 711,654 shares during the period. Heartland Advisors Inc. boosted its stake in shares of Accuray by 14.1% during the 4th quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider's stock valued at $7,573,000 after purchasing an additional 472,800 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Accuray by 1,123.1% during the fourth quarter. Mackenzie Financial Corp now owns 272,846 shares of the medical equipment provider's stock worth $540,000 after acquiring an additional 250,539 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Accuray by 482.4% during the fourth quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider's stock worth $481,000 after acquiring an additional 201,037 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Accuray by 6.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider's stock worth $5,900,000 after acquiring an additional 189,414 shares in the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Stock Up 1.1%

Shares of ARAY stock traded up $0.02 during trading hours on Tuesday, reaching $1.36. 428,392 shares of the stock were exchanged, compared to its average volume of 776,716. Accuray Incorporated has a 12-month low of $1.14 and a 12-month high of $2.95. The company's 50-day moving average price is $1.43 and its 200-day moving average price is $1.74. The company has a debt-to-equity ratio of 3.35, a current ratio of 1.64 and a quick ratio of 0.92.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. Accuray had a net margin of 0.14% and a return on equity of 1.43%. The business had revenue of $113.24 million for the quarter, compared to analyst estimates of $101.53 million. Analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Accuray from a "hold" rating to a "buy" rating in a research report on Friday, May 30th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.